- Home
- CUE vs IPSC Comparison
CUE vs IPSC Comparison
Compare CUE & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- IPSC
- Stock Information
- Founded
- CUE 2014
- IPSC 2019
- Country
- CUE United States
- IPSC United States
- Employees
- CUE N/A
- IPSC N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- CUE Health Care
- IPSC Health Care
- Exchange
- CUE Nasdaq
- IPSC Nasdaq
- Market Cap
- CUE 48.0M
- IPSC 49.6M
- IPO Year
- CUE 2018
- IPSC 2021
- Fundamental
- Price
- CUE $0.70
- IPSC $0.58
- Analyst Decision
- CUE Strong Buy
- IPSC Strong Buy
- Analyst Count
- CUE 3
- IPSC 5
- Target Price
- CUE $3.00
- IPSC $3.33
- AVG Volume (30 Days)
- CUE 220.4K
- IPSC 886.3K
- Earning Date
- CUE 08-13-2025
- IPSC 08-07-2025
- Dividend Yield
- CUE N/A
- IPSC N/A
- EPS Growth
- CUE N/A
- IPSC N/A
- EPS
- CUE N/A
- IPSC N/A
- Revenue
- CUE $7,991,000.00
- IPSC $114,898,000.00
- Revenue This Year
- CUE N/A
- IPSC $1,064.82
- Revenue Next Year
- CUE $23.84
- IPSC N/A
- P/E Ratio
- CUE N/A
- IPSC N/A
- Revenue Growth
- CUE 13.83
- IPSC 8286.72
- 52 Week Low
- CUE $0.45
- IPSC $0.34
- 52 Week High
- CUE $1.99
- IPSC $3.29
- Technical
- Relative Strength Index (RSI)
- CUE 55.84
- IPSC 52.16
- Support Level
- CUE $0.54
- IPSC $0.58
- Resistance Level
- CUE $0.66
- IPSC $0.66
- Average True Range (ATR)
- CUE 0.06
- IPSC 0.04
- MACD
- CUE 0.01
- IPSC -0.00
- Stochastic Oscillator
- CUE 81.98
- IPSC 41.52
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.